[1]
|
R. S. Fisher, W. van Emde Boas, W. Blume, C. Elger, P. Genton, P. Lee and J. J. Engel, “Epileptic Seizures and Epilepsy: Definitions Proposed by the International League against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE),” Epilepsia, Vol. 46, No. 4, 2005, pp. 470472. doi:10.1111/j.0013-9580.2005.66104.x
|
[2]
|
A. C. Gerlach and J. L. Krajewski, “Antiepileptic Drug Discovery and Development: What Have We Learned and Where Are We Going?” Pharmaceuticals, Vol. 3, No. 9, 2010, pp. 2884-2899. doi:10.3390/ph3092884
|
[3]
|
A. Chimirri, G. De Sarro, A. De Sarro, R. Gitto, S. Grasso, S. Quartarone, M. Zappalà, P. Giusti, V. Libri, A. Constanti and A. G. Chapman, “1-Aryl-3,5-dihydro4H-2,3-benzodiazepin-4-ones: Novel AMPA Receptor Antagonists,” Journal of Medicinal Chemistry, Vol. 40, No. 8, 1997, pp. 1258-1269. doi:10.1021/jm960506l
|
[4]
|
A. Chimirri, G. De Sarro, A. De Sarro, R. Gitto , S. Quartarone, M. Zappalà, A. Constanti and V. Libri, “3,5Dihydro-4H-2,3-benzodiazepine-4-thiones: A New Class of AMPA Receptor Antagonists,” Journal of Medicinal Chemistry , Vol. 41, No. 18, 1998, pp. 3409-3416.
doi:10.1021/jm9800393
|
[5]
|
M. Zappalà, R. Gitto, F. Bevacqua, S. Quartarone, A. Chimirri, M. Rizzo, G. D. Sarro and A. D. Sarro, “Synthesis and Evaluation of Pharmacological and Pharmacokinetic Properties of 11H-[1,2,4]triazolo[4,5-c][2,3] benzodiazepin-3(2H)-ones,” Journal of Medicinal Chemistry, Vol. 43, No. 25, 2000, pp. 4834-4839.
doi:10.1021/jm001012y
|
[6]
|
M. Zappalà, G. Postorino, N. Micale, S. Caccamese, N. Parrinello, G. Grazioso, G. Roda, F. S. Menniti, G. D. Sarro and S. Grasso, “Synthesis, Chiral Resolution, and Enantiopharmacology of a Potent 2,3-Benzodiazepine Derivative as Noncompetitive AMPA Receptor Antagonis,” Journal of Medicinal Chemistry, Vol. 49, No. 2, 2006, pp. 575-581. doi:10.1021/jm050552y
|
[7]
|
Y. Wang, C. S. Konkoy, V. I. Ilyin, K. E. Vanover, R. B. Carter, E. Weber, J. F. Keana, R. M. Woodward and S. X. Cai, “Synthesis of 7,8-(Methylenedioxy)-1-phenyl-3,5-dihydro-4H-2,3-benzodiazepin-4-ones as Novel and Potent Noncompetitive AMPA Receptor Antagonists,” Journal of Medicinal Chemistry, Vol. 41, No. 14, 1998, pp. 26212625. doi:10.1021/jm980168j
|
[8]
|
G. Abrahám, S. Sólyom, E. Csuzdi, P. Berzsenyi , I. Ling, I. Tarnawa, T. Hámori, I. Pallagi, K. Horváth, F. Andrási, G. Kapus, L. G. J. Hársing, I. Király, M. Patthy and G. Horváth, “New Noncompetitive AMPA Antagonists,” Bioorganic & Medicinal Chemistry, Vol. 8, No. 8, 2000, pp. 2127-2143 doi:10.1016/S0968-0896(00)00133-4
|
[9]
|
T. Hámore, S. Sólyom, P. Berzsenyi, F. Andrási and I. Tarnawa, “Structural Analogues of Some Highly active Non-Competitive AMPA Antagonists,” Bioorganic & Medicinal Chemistry Letters, Vol. 10, No. 9, 2000, pp. 899902. doi:10.1016/S0960-894X(00)00117-7
|
[10]
|
S. Grasso, G. De Sarro, A. De Sarro, N. Micale, M. Zappalà, G. Puia, M. Baraldi and C. D. Micheli, “Synthesis and Anticonvulsant Activity of Novel and Potent 2,3Benzodiazepine AMPA/Kainate Receptor Antagonists,” Journal of Medicinal Chemistry, Vol. 42, 1999, pp. 44144421. doi:10.1021/jm991086d
|
[11]
|
J. J. Luszczki, “Third-Generation Antiepileptic Drugs: Mechanisms of Action, Pharmacokinetics and Interactions,” Pharmacological Reports, Vol. 61, No. 2, 2009, pp. 197-216
|
[12]
|
M. L. Barreca, R. Gitto, S. Quartarone, D. L. Luca, G. D. Sarro and A. Chimirri, “Pharmacophore Modeling as an Efficient Tool in the Discovery of Novel Noncompetitive,” Journal of Chemical Information and Modeling, Vol. 43, No. 2, 2003, pp. 651-655.doi:10.1021/ci025625q
|
[13]
|
J. F. Howes and C. Bell, “Talampanel,” Neurotherapeutics, Vol. 4, No. 1, 2007, pp. 126-129.
doi:10.1016/j.nurt.2006.11.001
|
[14]
|
R. Gitto, R. Caruso, V. Orlando, S. Quartarone, M. L. Barreca, G. Ferreri, E. Russo, G. D. Sarro and A. Chimirri, “Synthesis and Anticonvulsant Properties of Tetrahydroisoquinoline Derivative,” Farmaco, Vol. 59, No. 1, 2004, pp. 7-12. doi:10.1016/j.farmac.2003.10.003
|
[15]
|
R. Gitto, R. Caruso, B. Pagano, L. D. Luca, R. Citraro, E. Russo, G. D. Sarro and A. Chimirri, “Novel Potent Anticonvulsant Agent Containing a Tetrahydroisoquinoline Kkeleton,” Journal of Medicinal Chemistry, Vol. 49, No. 18, 2006, pp. 5618-5622.
doi:10.1021/jm060411b
|
[16]
|
R. Gitto, B. Pagano, R. Citrato, F. Scicchitano, G. D. Sarro and A. Chimirri, “Solution-Phase Parallel Synthesis and Evaluation of Anticonvulsant Activity of N-Substituted3,4-dihydroisoquinoline-2(1H)-carboxamides,” European Journal of Medicinal Chemistry, Vol. 44, No. 3, 2009, pp. 1349-1354. doi:10.1016/j.ejmech.2008.02.025
|
[17]
|
L. De Luca, R. Gitto, M. L. Barreca, R. Caruso, S. Quartarone, R. Citraro, G. D. Sarro and A. Chimirri, “3D Pharmacophore Models for 1,2,3,4-Tetrahydroisoquinoline Derivatives Acting as Anticonvulsant Agents,” Archiv der Pharmazie Chemistry in Life Sciences, Vol. 339, No. 7, 2006, pp. 388-400.
|
[18]
|
K. J. Bough and D. A. Engel, “Comparison of the Anticonvulsant Efficacies and Neuroroxic Effects of Valproic Acid, Phehytoin, and the Ketogenic Diet,” Epilepsia, Vol. 42, No. 10, 2001, pp. 1345-1353.
doi:10.1046/j.1528-1157.2001.08901.x
|
[19]
|
J. B. Monent, I. Jorquera, I. Mazzucchelli, A. Depaulis, E. Perucca, Y. Ben-Ari and A. Represa, “Fetal Exposure to GABA-Acting Antiepileptic Drugs Generates Hippocampal and Cortical Dyspkasias,” Epilepsia, Vol. 48, No. 4, 2007, pp. 684-693.
doi:10.1111/j.1528-1167.2007.01056.x
|
[20]
|
V. B. Brito, V. Folmer, G. O. Puntel, R. Fachinetto, J. C. Soares, G. Zeni, C. W. Nogueira and J. B. Rocha, “Diphenyl Diselenide and 2,3-Dimercaptopropanol Increase the PTZ-Induced Chemical Seizure and Mortality in Mice,” Brain Research Bulletin, Vol. 68, No. 6, 2006, pp. 414418.
|
[21]
|
A. Ilhan, M. A. Aladag, A. Kocer, A. Boluk, A. Gurel and F. Armutcu, “Erdosteine Ameliorates PTZ-Induced Oxidative Stress in Mice Seizure Model,” Brain Research Bulletin, Vol. 30, No. 6, 2005, pp. 495-499.
doi:10.1016/j.brainresbull.2005.02.027
|
[22]
|
N. B. Agarwal, S. Jain, D. Nagpal, N. K. Agarwal, P. K. Mediratta, K. K. Sharma, “Liposomal Formulation of Curcumin Attenuates Seizures in Different Experimental Models of Epilepsy in Mice,” Fundamental & Clinical Pharmacology, 2011.
doi:10.1111/j.1472-8206.2011.01002.x
|
[23]
|
A. Zandieh, F. Maleki, A. Hajimirzabeigi, B. Zandieh, O. Khalilzadeh and A. R. Dehpour, “Anticonvulsant Effect of Celecoxib on Pentylenetetrazole-Induced Convulsion: Modulation by NO Pathway,” Acta Neurobiologiae Experimentalis, Vol. 70, No. 4, 2010, pp. 390-397.
|